Healthcare Wrap Week 19: Raisings, Trial Data and Boardroom Resets Drive Trading

• ImpediMed led the downside after a deeply dilutive funding round, while Proteomics and Hydration Pharmaceuticals also fell hard.
• Clinical news stayed busy, with Entropy, PYC and Neuren all reporting progress that kept investors engaged.
• Medtech and healthcare service names such as Resonance, Nova Eye and Sigma pointed to stronger sales or better margins.
• Leadership upheaval at Arovella and management change at Cann Group added uncertainty even where clinical plans remained in place.